Trial · NCT01023178
Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure
NCT01023178, Not applicable, Completed, Stanford University; results first posted 2017-01-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure. Trials, record NCT01023178. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01023178
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure
- NCT number
- NCT01023178
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 20 participants, actual
- Lead sponsor
- Stanford University
- Conditions
- Ovarian Failure, Premature
- Interventions
- 17beta Estradiol, Conjugated estrogens, 17Beta Estradiol - transdermal, Progesterone, micronized
- First posted
- 2009-12-02
- Last updated
- 2017-01-20
- Results first posted
- 2017-01-20
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Estradiol | end of study (up to 2 years) | Estradiol blood levels at end of study compared across groups to determine effect of dosing methods. Significance of levels depends on the stage of puberty and goals of therapy. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Estradiol | end of study (up to 2 years) | pg/mL | MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Estradiol | Transdermal 17Beta Estradiol | 53 | Standard Error 19 | pg/mL | |
| Estradiol | Oral Conjugated Equine Estrogen | 14 | Standard Error 5 | pg/mL | |
| Estradiol | Oral 17beta Estradiol | 12 | Standard Error 5 | pg/mL |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Transdermal 17Beta Estradiol | 5 | |
| Overall Study | STARTED | Oral Conjugated Equine Estrogen | 8 | |
| Overall Study | STARTED | Oral 17beta Estradiol | 7 | |
| Overall Study | COMPLETED | Transdermal 17Beta Estradiol | 3 | |
| Overall Study | COMPLETED | Oral Conjugated Equine Estrogen | 6 | |
| Overall Study | COMPLETED | Oral 17beta Estradiol | 4 | |
| Overall Study | NOT COMPLETED | Transdermal 17Beta Estradiol | 2 | |
| Overall Study | NOT COMPLETED | Oral Conjugated Equine Estrogen | 2 | |
| Overall Study | NOT COMPLETED | Oral 17beta Estradiol | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Transdermal 17Beta Estradiol | ||
| Total, all-cause mortality | Oral Conjugated Equine Estrogen | ||
| Total, all-cause mortality | Oral 17beta Estradiol | ||
| Total, other adverse events | Transdermal 17Beta Estradiol | 0 | 5 |
| Total, other adverse events | Oral Conjugated Equine Estrogen | 0 | 8 |
| Total, other adverse events | Oral 17beta Estradiol | 0 | 7 |
| Total, serious adverse events | Transdermal 17Beta Estradiol | 0 | 5 |
| Total, serious adverse events | Oral Conjugated Equine Estrogen | 0 | 8 |
| Total, serious adverse events | Oral 17beta Estradiol | 0 | 7 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 24982681 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01023178
GET https://conductscience.org/api/trials/v1/NCT01023178/registered